Cargando…

Engineering multi-specific antibodies against HIV-1

As increasing numbers of broadly neutralizing monoclonal antibodies (mAbs) against HIV-1 enter clinical trials, it is becoming evident that combinations of mAbs are necessary to block infection by the diverse array of globally circulating HIV-1 strains and to limit the emergence of resistant viruses...

Descripción completa

Detalles Bibliográficos
Autores principales:	Padte, Neal N., Yu, Jian, Huang, Yaoxing, Ho, David D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6114543/ https://www.ncbi.nlm.nih.gov/pubmed/30157871 http://dx.doi.org/10.1186/s12977-018-0439-9

Ejemplares similares

The influence of proline isomerization on potency and stability of anti-HIV antibody 10E8
por: Guttman, Miklos, et al.
Publicado: (2020)

In Vivo Production of Monoclonal Antibodies by Gene Transfer via Electroporation Protects against Lethal Influenza and Ebola Infections
por: Andrews, Chasity D., et al.
Publicado: (2017)

Quantifying the contribution of Fc-mediated effector functions to the antiviral activity of anti–HIV-1 IgG1 antibodies in vivo
por: Wang, Pengfei, et al.
Publicado: (2020)

Natural and engineered antibodies against HIV
por: Berger, Edward A
Publicado: (2006)

Recent Progress toward Engineering HIV-1-Specific Neutralizing Monoclonal Antibodies
por: Sun, Ming, et al.
Publicado: (2016)

Identification and specificity of broadly neutralizing antibodies against HIV
por: McCoy, Laura E., et al.
Publicado: (2017)

Three Recombinant Engineered Antibodies against Recombinant Tags with High Affinity and Specificity
por: Zhao, Hongyu, et al.
Publicado: (2016)

Engineered Antigen-Specific T Cells Secreting Broadly Neutralizing Antibodies: Combining Innate and Adaptive Immune Response against HIV
por: Powell, Allison B., et al.
Publicado: (2020)

Virus-Like Particle Based Vaccines Elicit Neutralizing Antibodies against the HIV-1 Fusion Peptide
por: Mogus, Alemu Tekewe, et al.
Publicado: (2020)

Engineered RBCs Encapsulating Antigen Induce Multi-Modal Antigen-Specific Tolerance and Protect Against Type 1 Diabetes
por: Raposo, Colin J., et al.
Publicado: (2022)

Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization
por: Wang, Pengfei, et al.
Publicado: (2021)

Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization
por: Wang, Pengfei, et al.
Publicado: (2021)

In vivo expressed biologics for infectious disease prophylaxis: rapid delivery of DNA-based antiviral antibodies
por: Andrews, Chasity D., et al.
Publicado: (2020)

2549 Characterizing the expression kinetics of HIV-1 envelope protein
por: Oh, Djin-Ye, et al.
Publicado: (2018)

B cell engineering in vivo: Accelerating induction of broadly neutralizing antibodies against HIV-1 infection
por: Sun, Caijun, et al.
Publicado: (2023)

Multi-Attribute Monitoring Method for Process Development of Engineered Antibody for Site-Specific Conjugation
por: Hines, Alistair R., et al.
Publicado: (2023)

Natural Variation in Vif: Differential Impact on APOBEC3G/3F and a Potential Role in HIV-1 Diversification
por: Simon, Viviana, et al.
Publicado: (2005)

Development of Antibodies with Broad Neutralization Specificities against HIV-1 after Long Term SHIV Infection in Macaques
por: Gao, Nan, et al.
Publicado: (2020)

Engineering antibody-like inhibitors to prevent and treat HIV-1 infection
por: Gardner, Matthew R., et al.
Publicado: (2017)

Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies
por: Cerutti, Gabriele, et al.
Publicado: (2021)

Induction of cross-reactive HIV-1 specific antibody responses by engineered V1V2 immunogens with reduced conformational plasticity
por: Lai, Jennifer I., et al.
Publicado: (2020)

Synthetic glycopeptides reveal the glycan specificity of HIV-neutralizing antibodies
por: Amin, Mohammed N., et al.
Publicado: (2013)

Engineering pan–HIV-1 neutralization potency through multispecific antibody avidity
por: Rujas, Edurne, et al.
Publicado: (2022)

An end-to-end automated platform process for high-throughput engineering of next-generation multi-specific antibody therapeutics
por: Furtmann, Norbert, et al.
Publicado: (2021)

Implementation of a three-tiered approach to identify and characterize anti-drug antibodies raised against HIV-specific broadly neutralizing antibodies
por: Bharadwaj, Pranay, et al.
Publicado: (2020)

Broadly Neutralizing Antibodies against HIV-1 As a Novel Aspect of the Immune Response
por: Shcherbakov, D. N., et al.
Publicado: (2015)

The CD20-specific engineered toxin antibody MT-3724 exhibits lethal effects against mantle cell lymphoma
por: Huang, Shengjian, et al.
Publicado: (2018)

Cattle engineered to produce human antibodies against coronavirus
por: Bray, Natasha
Publicado: (2016)

Antibody Conjugates for Targeted Therapy Against HIV-1 as an Emerging Tool for HIV-1 Cure
por: Umotoy, Jeffrey C., et al.
Publicado: (2021)

An Overview of Human Anti-HIV-1 Neutralizing Antibodies against Diverse Epitopes of HIV-1
por: Kumar, Sanjeev, et al.
Publicado: (2023)

Harnessing Natural Mosaics: Antibody-Instructed, Multi-Envelope HIV-1 Vaccine Design
por: Sealy, Robert E., et al.
Publicado: (2021)

Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques
por: Shen, Xiaoying, et al.
Publicado: (2017)

Engineered immunogens to elicit antibodies against conserved coronavirus epitopes
por: Kapingidza, A. Brenda, et al.
Publicado: (2023)

Picomolar Dichotomous Activity of Gnidimacrin Against HIV-1
por: Huang, Li, et al.
Publicado: (2011)

The interdependence of antibody C and V regions on specificity and affinity: Significant implications for the engineering of therapeutic antibodies
por: Nosanchuk, Joshua D.
Publicado: (2013)

Vaccine-induced V1V2-specific antibodies control and or protect against infection with HIV, SIV and SHIV
por: Zolla-Pazner, Susan, et al.
Publicado: (2019)

Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7
por: Wang, Pengfei, et al.
Publicado: (2021)

Vaccine elicitation of HIV broadly neutralizing antibodies from engineered B cells
por: Huang, Deli, et al.
Publicado: (2020)

A Recoding Method to Improve the Humoral Immune Response to an HIV DNA Vaccine
por: Huang, Yaoxing, et al.
Publicado: (2008)

Polyfunctional HIV-Specific Antibody Responses Are Associated with Spontaneous HIV Control
por: Ackerman, Margaret E., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_8a4vh65r59krf92od7fngt90v3